Browse > Article
http://dx.doi.org/10.1080/12298093.2020.1746064

The Antiproliferation Activity of Ganoderma formosanum Extracts on Prostate Cancer Cells  

Chiang, Cheng-Yen (Division of Urology, Department of Surgery, Taoyuan General Hospital, Ministry of Health and Welfare)
Hsu, Kai-Di (Institute of Biotechnology, National Taiwan University)
Lin, Yen-Yi (Institute of Biotechnology, National Taiwan University)
Hsieh, Chang-Wei (Department of Food Science and Biotechnology, National Chung Hsing University)
Liu, Jui-Ming (Division of Urology, Department of Surgery, Taoyuan General Hospital, Ministry of Health and Welfare)
Lu, Tze-Ying (Department of Internal Medicine, Taipei Medical University-Shuang Ho Hospital)
Cheng, Kuan-Chen (Institute of Biotechnology, National Taiwan University)
Publication Information
Mycobiology / v.48, no.3, 2020 , pp. 219-227 More about this Journal
Abstract
Androgen-independent prostate cancer accounts for mortality in the world. In this study, various extracts of a medical fungus dubbed Ganoderma formosanum were screened for inhibition of DU145 cells, an androgen-independent prostate cancer cell line. Results demonstrated that both hexane (GF-EH) and butanol (GF-EB) fraction of G. formosanum ethanol extract inhibited DU145 cell viability in a dose-dependent manner. GF-EH induced cell-cycle arrest in G1 phase of DU145 cells via downregulation of cyclin E2 protein expression. In addition, GF-EB triggered extrinsic apoptosis of DU145 cells by activating caspase 3 gene expression resulting in programed cell death. Above all, both GF-EH and GF-EB show lower toxicity to normal human fibroblast cell line compared to DU145 cell, implying that they possess specific drug action on cancer cells. This study provides a molecular basis of G. formosanum extract as a potential ingredient for treatment of androgen-independent prostate cancer.
Keywords
Prostate cancer; Ganoderma formosanum; cell cycle arrest; cyclin; apoptosis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Siegel RL, Miller KD, Fedewa SA et al. Colorectal cancer statistics. CA Cancer J Clin. 2017;67(3):177-193.   DOI
2 Huang S-Y, Huang G-J, Wu H-C, et al. Ganoderma tsugae inhibits the SREBP-1/AR axis leading to suppression of cell growth and activation of apoptosis in prostate cancer cells. Molecules. 2018;23(10):2539.   DOI
3 Qu L, Li S, Zhuo Y, et al. Anticancer effect of triterpenes from Ganoderma lucidum in human prostate cancer cells. Oncol Lett. 2017;14(6):7467-7472.
4 Hsu K-D, Cheng K-C. From nutraceutical to clinical trial: frontiers in ganoderma development. Appl Microbiol Biotechnol. 2018;102(21):9037-9051.   DOI
5 Wu G-S, Guo J-J, Bao J-L, et al. Anti-cancer properties of triterpenoids isolated from Ganoderma lucidum-a review. Expert Opin Invest Drugs. 2013;22(8):981-992.   DOI
6 Johnson BM, Doonan BP, Radwan FF, et al. Ganoderic acid DM: an alternative agent for the treatment of advanced prostate cancer. Open Prost Cancer J. 2010; 3:78-85.   DOI
7 Liu J, Shimizu K, Konishi F, et al. The anti-androgen effect of ganoderol B isolated from the fruiting body of Ganoderma lucidum. Bioorg Med Chem. 2007;15(14):4966-4972.   DOI
8 Zaidman B-Z, Wasser SP, Nevo E, et al. Androgen receptor-dependent and-independent mechanisms mediate Ganoderma lucidum activities in LNCaP prostate cancer cells. Int J Oncol. 2007;31(4):959-967.
9 Hsu K-D, Chen H-J, Wang C-S, et al. Extract of Ganoderma formosanum mycelium as a highly potent tyrosinase inhibitor. Sci Rep. 2016;6:32854.   DOI
10 Hsu K-D, Chan Y-H, Chen H-J, et al. Tyrosinasebased TLC autography for anti-melanogenic drug screening. Sci Rep. 2018;8(1):401.   DOI
11 Hsu K-D, Wu S-P, Lin S-P, et al. Enhanced active extracellular polysaccharide production from Ganoderma formosanum using computational modeling. J Food Drug Anal. 2017;25(4):804-811.   DOI
12 Zaidman B-Z, Wasser SP, Nevo E, et al. Coprinus comatus and Ganoderma lucidum interfere with androgen receptor function in LNCaP prostate cancer cells. Mol Biol Rep. 2008;35(2):107-117.   DOI
13 Kao CH, Bishop KS, Xu Y, et al. Identification of potential anticancer activities of novel Ganoderma lucidum extracts using gene expression and pathway network analysis. Genomics Insights. 2016;9:GEI. S32477.
14 Wang C-L, Lu C-Y, Hsueh Y-C, et al. Activation of antitumor immune responses by Ganoderma formosanum polysaccharides in tumor-bearing mice. Appl Microbiol Biotechnol. 2014;98(22):9389-9398.   DOI
15 Litwin MS, Tan HJ. The diagnosis and treatment of prostate cancer: a review. JAMA. 2017;317(24):2532-2542.   DOI
16 Zhu M, Zheng Z, Huang J, et al. Modulation of miR-34a in curcumin-induced antiproliferation of prostate cancer cells. J Cell Biochem. 2019;120(9):15616-15624.   DOI
17 Cao Y, Xu X, Liu S, et al. Ganoderma: a cancer immunotherapy review. Front Pharmacol. 2018;9:1217.   DOI
18 Zhang JH, Xu M. DNA fragmentation in apoptosis. Cell Res. 2000;10(3):205-211.   DOI
19 Ouyang L, Shi Z, Zhao S, et al. Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif. 2012;45(6):487-498.   DOI
20 Hsin I-L, Ou C-C, Wu M-F, et al. GMI, an immunomodulatory protein from Ganoderma microsporum, potentiates cisplatin-induced apoptosis via autophagy in lung cancer cells. Mol Pharmaceutics. 2015;12(5):1534-1543.   DOI
21 Dan X, Liu W, Wong JH, et al. A ribonuclease isolated from wild Ganoderma lucidum suppressed autophagy and triggered apoptosis in colorectal cancer cells. Front Pharmacol. 2016;7:217.
22 Gong D, Ferrell JE. The roles of cyclin A2, B1, and B2 in early and late mitotic events. Mol Biol Cell. 2010;21(18):3149-3161.   DOI
23 Takahashi A, Kimura F, Yamanaka A, et al. Metformin impairs growth of endometrial cancer cells via cell cycle arrest and concomitant autophagy and apoptosis. Cancer Cell Int. 2014;14(1):53.   DOI
24 Smith ML, Murphy K, Doucette CD, et al. The dietary flavonoid fisetin causes cell cycle arrest, caspase-dependent apoptosis, and enhanced cytotoxicity of chemotherapeutic drugs in triple-negative breast cancer cells. J Cell Biochem. 2016; 117(8):1913-1925.   DOI
25 Sherr CJ, Bartek J. Cell cycle-targeted cancer therapies. Annu Rev Cancer Biol. 2017;1(1):41-57.   DOI
26 Gudas JM, Payton M, Thukral S, et al. Cyclin E2, a novel G(1) cyclin that binds Cdk2 and is aberrantly expressed in human cancers. Mol Cell Biol. 1999;19(1):612-622.   DOI
27 Bolognese F, Wasner M, Dohna CL, et al. The cyclin B2 promoter depends on NF-Y, a trimer whose CCAAT-binding activity is cell-cycle regulated. Oncogene. 1999;18(10):1845-1853.   DOI